文献速递炎症性肠病

托法替布溃疡性结肠炎临床开发项目中的静脉血栓栓塞事件

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-09

该分析基于托法替布溃疡性结肠炎项目(1项2期、2项3期诱导、1项3期维持及1项长期扩展研究),评估深静脉血栓和肺栓塞发生率。总体队列1157例患者(2404患者年暴露)中,1例发生深静脉血栓(发生率0.04/100患者年,95%CI 0.00-0.23),4例发生肺栓塞(0.16/100患者年,95%CI 0.04-0.41),所有事件均发生于长期扩展研究且患者以10mg每日两次为主,并伴有静脉血栓栓塞危险因素。

要点

  • 总体队列中深静脉血栓发生率0.04/100患者年,肺栓塞0.16/100患者年。
  • 所有静脉血栓栓塞事件均发生于长期扩展研究,患者以10mg每日两次为主。
  • 发生事件的患者均伴有静脉血栓栓塞危险因素及溃疡性结肠炎。

核心结论

  • 在托法替布溃疡性结肠炎项目中,深静脉血栓和肺栓塞发生率较低,事件均发生于长期扩展研究且患者以10mg每日两次为主并伴有静脉血栓栓塞危险因素。

研究设计与样本

  • 事后分析,纳入1项2期、2项3期诱导、1项3期维持及1项正在进行的开放标签长期扩展研究(2018年9月数据截止)。
  • 总体队列1157例患者,累积2404患者年暴露,托法替布治疗最长6.1年。

主要发现

  • 诱导期:安慰剂组1例深静脉血栓、1例肺栓塞,托法替布组无事件。
  • 维持期:安慰剂组1例深静脉血栓、1例肺栓塞,托法替布组无事件。
  • 总体队列:1例深静脉血栓(发生率0.04/100患者年,95%CI 0.00-0.23),4例肺栓塞(0.16/100患者年,95%CI 0.04-0.41)。
  • 所有事件均发生于长期扩展研究,患者以10mg每日两次为主(总体队列83%患者以10mg每日两次为主),且均伴有静脉血栓栓塞危险因素。

临床怎么用

  • 在溃疡性结肠炎患者使用托法替布前及治疗中,应评估静脉血栓栓塞危险因素,尤其对计划使用10mg每日两次者。

局限性

  • 样本量小且药物暴露时间有限,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). AIM: To report incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the tofacitinib UC programme. METHODS: DVT and PE were evaluated from one phase 2 and two phase 3 induction studies, one phase 3 maintenance study and an ongoing, open-label, long-term extension (OLE) study (September 2018 datacut). Data were analysed in induction, maintenance and overall (patients receiving ≥ 1 dose of tofacitinib 5 or 10 mg b.d. in any phase 2, 3 or OLE study) cohorts. RESULTS: 1157 patients (2404 patient-years' exposure; ≤ 6.1 years' tofacitinib treatment) were evaluated in the overall cohort. In induction, one placebo-treated patient had DVT and one had PE; no tofacitinib-treated patients had DVT/PE. In maintenance, one placebo-treated patient had DVT and one had PE; no tofacitinib-treated patients had DVT/PE. In the overall cohort, one patient had DVT (incidence rate [patients with events/100 patient-years; 95% CI]: 0.04 [0.00-0.23]); four had PE (0.16 [0.04-0.41]); all received predominant dose tofacitinib 10 mg b.d.; all had venous thromboembolism risk factors alongside UC. CONCLUSIONS: In this post hoc analysis of patients with UC, during tofacitinib exposure, one patient had DVT and four had PE, all during the OLE study, on predominant dose 10 mg b.d. (83% of overall cohort patients received predominant dose 10 mg b.d.) with venous thromboembolism risk factors. This analysis is limited by small sample size and limited drug exposure; further studies are needed. ClinicalTrials.gov: NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, Panés J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019. PMID: 31599001. doi:10.1111/apt.15514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。